Edinburgh medtech Manus Neurodynamica has raised £1.2 million in funding for the launch of its NeuroMotor Pen, which provides early warnings of neurological conditions such as Parkinson’s disease.
The pen will launch later in 2021, initially in the UK and Benelux markets, with work in progress for US regulatory approval. Parkinson’s disease is the world’s fastest-growing neurological condition, with an estimated 145,000 people in the UK living with the condition.
The NeuroMotor Pen uses sensors linked to analytical software which analyse limb and hand movements to help enable doctors to assess whether a patient is displaying early signs of neurological conditions.
The product, which is CE-marked, is a quick, non-invasive and inexpensive diagnostic aid which can assist doctors in the ongoing monitoring of neurological conditions like Parkinson’s.
Following the latest funding round, and a £750,000 financing round which closed in May 2020, Manus Neurodynamica has now raised £5 million to date.
Manus Neurodynamica CEO Dr Rutger Zietsma said: “2021 looks set to be an extremely busy year for Manus. Having spent more than 10 years developing, trialling and refining our first product, we can finally look forward to seeing our NeuroMotor Pens implemented more broadly and making a real difference to the lives of people living with Parkinson’s and other neurological conditions.”
“Through faster and simpler diagnoses and objective patient monitoring with digital record keeping, we can help streamline the pathway and deliver more successful treatment outcomes for the fastest growing neurological condition in the world.”